Dr. Lenz on Next Steps With Immunotherapy in mCRC
Dr Lenz on Frontline Nivolumab Plus Ipilimumab in MSI-H/dMMR mCRCПодробнее
Dr. Lenz on Potential for Immunotherapy in mCRCПодробнее
Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRCПодробнее
Dr. Lenz Discusses Frontline Nivolumab Plus Ipilimumab in mCRCПодробнее
Dr. Lenz on Need for New Treatment Strategies in Colorectal CancerПодробнее
Dr. Lenz on Later-Line Combo Approaches in CRCПодробнее
Dr. Lenz on Updated Results of the CheckMate-142 Trial in mCRCПодробнее
Dr. Overman on Next Steps With Immunotherapy in mCRCПодробнее
Dr. Lenz on Updated Data From CheckMate 142 With Nivolumab + Ipilimumab in mCRCПодробнее
Debate: MSI High Colon Cancer - ImmunotherapyПодробнее
Second-Line Therapy for RAS Wild-Type mCRCПодробнее
Dr. Bendell on the Next Steps Following Progression on Immunotherapy in MSI-H CRCПодробнее
Immunotherapy in MSI-H/dMMR mCRC: first-line options and dual checkpoint inhibition insightsПодробнее
Key challenges in the treatment of colorectal cancerПодробнее
Dr. Lenz on Breakthrough Designation of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRCПодробнее
Dr. Lenz on the Changing Landscape of Metastatic Colorectal CancerПодробнее
Nivolumab plus low-dose ipilimumab promising for treatment-naïve MSI-high mCRC | Heinz-Josef LenzПодробнее
Dr. Lenz on the Benefit of Regorafenib in CRCПодробнее
Dr. Lenz Discusses Targeted Combinations in Colorectal CancerПодробнее
